Results 11 to 20 of about 19,649 (222)

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148 [PDF]

Cell Death & Differentiation, 1998
The BCR - ABL tyrosine kinase has been implicated as the cause of Philadelphia chromosome (Ph1)-positive leukemias. We report herein that CGP 57148, a selective inhibitor of the ABL tyrosine kinase, caused apoptosis specifically in bcr - abl-positive chronic myelogenous leukemia (CML) cells, K562 and KYO-1.
S, Dan, M, Naito, T, Tsuruo
openaire   +4 more sources

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Blood, 2007
Abstract Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations. In this phase 2 open-label study, 400 mg nilotinib was administered orally twice daily to 280 patients with Philadelphia chromosome ...
KANTARJIAN HM, GILES F, GATTERMANN N, BHALLA K, ALIMENA, Giuliana, PALANDRI F, OSSENKOPPELE GJ, NICOLINI FE, O'BRIEN SG, LITZOW M, BHATIA R, CERVANTES F, HAQUE A, SHOU Y, RESTA DJ, WEITZMAN A, HOCHHAUS A, LE COUTRE P.   +17 more
openaire   +6 more sources

Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines. [PDF]

J Cell Mol Med
ABSTRACT Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)‐driven leukaemias. Asciminib offers a novel therapeutic option; however, resistance continues to emerge. We hypothesised that targeting proteostasis and epigenetic regulation with bortezomib and panobinostat could ...
Okabe S, Yoshizawa S, Arai Y, Gotoh A, Akahane D.   +4 more
europepmc   +2 more sources

Ten-Year Outcome of a Patient With Concurrent Pelvic Myeloid Sarcoma and Underlying Chronic Myeloid Leukaemia in Chronic Phase: A Case Report and Literature Review. [PDF]

Cancer Rep (Hoboken)
ABSTRACT Background Myeloid sarcoma is a rare solid tumour of immature myeloid precursors occurring in an extramedullary site. It often presents significant diagnostic and therapeutic challenges to clinical haematologists. Case We describe a previously healthy patient who presented simultaneously with hyperleucocytic chronic myeloid leukaemia in ...
Yong KY, Lim SH, Lau LG, Chew LP.
europepmc   +2 more sources

The Relationship Between the Type ofbcr-ablHybrid Messenger RNA and Thrombopoiesis in Philadelphia-Positive Chronic Myelogenous Leukemia [PDF]

Leukemia & Lymphoma, 1993
Formation of the Philadelphia (Ph1) chromosome, which contains the hybrid bcr-abl gene, is thought to be the initial event in chronic myelogenous leukemia (CML). The positions of the breakpoint within the breakpoint cluster region (bcr) on the bcr-abl gene in 22 chronic-phase cases of Ph1-positive CML were determined using conventional Southern blots ...
K, Inokuchi, T, Nomura
  +8 more sources

Leukemic infiltration of the ovary as an initial presentation of chronic myeloid leukemia in chronic phase [PDF]

Vojnosanitetski Pregled, 2022
Introduction. Extramedullary sites of leukemic proliferation, harboring an adverse outcome, are rare and usually found in the blastic phase of chronic myeloid leukemia.
Sekulić Borivoj, Perčić Ivanka, Dragičević-Jojkić Marina, Dokić Marina, Panjković Milana   +4 more
doaj   +1 more source

Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice

Hematology, Transfusion and Cell Therapy, 2022
Introduction: Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success.
Carla Boquimpani, Fernanda Salles Seguro, Gustavo Henrique Romani Magalhães, Ingrid Luise Soares Pinto, Israel Bendit, Jaisson André Pagnoncelli Bortolini, Katia Borgia Barbosa Pagnano, Renato Centrone, Vaneuza Funke   +8 more
doaj   +1 more source

Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia

Pharmacological Research, 2022
Chronic myelogenous leukemia (CML) is an indolent malignant hematological disease that accounts for about 15% of all cases of leukemia. This disorder results from the formation of the Philadelphia chromosome that involves a reciprocal translocation that produces a lengthened chromosome 9 and shortened chromosome 22 - the Philadelphia chromosome.
openaire   +2 more sources

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib [PDF]

Blood Cancer Journal, 2015
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL -positive chronic myelogenous leukemia treated with ruxolitinib and ...
Zhou, A, Knoche, E M, Engle, E K, Fisher, D A C, Oh, S T   +4 more
openaire   +1 more source

The Profile of BCR-ABL1 Fusion Gene in Childhood Leukemia at “Dharmais” Cancer Hospital

Indonesian Journal of Cancer, 2020
Background: BCR-ABL1 fusion gene, which originated from t (9;22), is an important biomarker for diagnosis, therapeutic approach, and prognosis in childhood leukemia.
Mururul Aisyi , Puji Lestari, Siti Nadliroh, Anita Meisita, Didin Solachudin, Dewi Kristanti, Adhitya Bayu Perdana, Bambang Karsono   +7 more
doaj   +1 more source